Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Clinical Trial FAQs About Us
Search BMS Clinical Trials
BMS Active Not Yet Recruiting Study icon

Active, Not Recruiting

Trial ID IM011-054  |   NCT04908202

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Warning icon
Sorry, this study is no longer accepting new participants, but is still ongoing.
You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.
Check Your Eligibility

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • BMS Active Not Yet Recruiting Study icon
    Active, Not Recruiting

Overview

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

print Print
email Email

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
    1. Meets the Classification Criteria for Psoriatic Arthritis at Screening.
      1. Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
        1. Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
          1. Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
            1. ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
              1. Must have completed the week 52 treatment for the optional open-label long-term extension period.

                Exclusion Criteria

                Exclusion Criteria Icon
                • Nonplaque psoriasis at screening or day 1.
                  1. Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.
                    1. History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).
                      1. Active fibromyalgia.
                        1. Received an approved or investigational biologic therapy for the treatment of PsA or PsO.
                          Additional Information *
                          • Other protocol-defined Inclusion/Exclusion criteria apply.

                            Treatment Options

                            Study Arms

                            ASSIGNED INTERVENTION

                            Study Arms

                            Experimental: Deucravacitinib

                            ASSIGNED INTERVENTION
                            • Drug: Deucravacitinib

                            Study Arms

                            Placebo Comparator: Placebo

                            ASSIGNED INTERVENTION
                            • Other: Placebo

                            Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you